FIA
REGN icon

FNY Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

FNY Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31K Hold
50
– – 0.01% 480
2026
Q1 		$38K Hold
50
– – 0.02% 398
2025
Q4 		$38K Buy
+50
New +$34K 0.01% 484
2025
Q3 		– Sell
-150
Closed -$78K – 1469
2025
Q2 		$78K Buy
+150
New +$83.7K 0.03% 330
2019
Q3 		– Sell
-7
Closed -$2K – 1116
2019
Q2 		$2K Buy
+7
New +$2.33K ﹤0.01% 847
2018
Q4 		– Sell
-36
Closed -$14K – 967
2018
Q3 		$14K Buy
+36
New +$13.7K ﹤0.01% 498

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

FNY Investment Advisers's REGN Position: Q2 2026 in Review

FNY Investment Advisers held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 50 shares worth $31K. The position accounts for 0.01% of the portfolio, ranked #480.

FNY Investment Advisers first reported a position in REGN in Q3 2018 and has held it in 6 quarters since. The position peaked at $78K in Q2 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • FNY Investment Advisers held 50 shares of Regeneron Pharmaceuticals worth $31K as of Q2 2026.
  • FNY Investment Advisers left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #480 holding.
  • FNY Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 6 quarters since.
  • FNY Investment Advisers's Regeneron Pharmaceuticals position peaked at $78K in Q2 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.